What’s holding up gene therapy? Making drugs on a large scale

gene
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

As interest in gene therapy grows, manufacturers face physical, biological, and engineering challenges to developing and producing drugs on a larger scale. “For early-stage Phase I trials, little material is required, but for Phase II and Phase III trials, or a licensed product, you need large-scale production equipment,” says Farzin Farzaneh, PhD, professor of molecular medicine at King’s College London.

Farzaneh’s lab participates in extensive academic and industrial collaborations, including projects to accelerate the development and clinical translation of viral vectors. According to him, a major challenge is the limited availability (and expense) of facilities that satisfy current good manufacturing practice (cGMP) requirements. Part of his lab’s collaborative work is developing closed manufacturing systems, which avoid problems with environmental and other contamination.

Related article:  Podcast: Gene therapy could be best hope to cure Duchenne muscular dystrophy

Manufacturing challenges are being addressed not only by academically oriented collaborations, such as those involving the Farzaneh lab, but also by collaborations between companies. For example, Symbiosis Pharmaceutical Services and Cobra Biologics recently completed a project to bring together expertise in viral vector and drug manufacturing.

If such production-enhancing innovations succeed, they will help ensure a bright future for gene therapy.

Read the original post

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend